STING Pathway Targeting Therapeutics and Technologies Market

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of therapeutics targeting STING pathway market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that provides details related to the STING pathway and its role in signaling. It further includes an elaborate discussion on the role of STING in oncological disorders, autoimmune diseases and antimicrobial host defense. Further, the chapter provides an overview of the compounds that can be used for activation or inhibition of the aforementioned pathway (agonists, antagonists, STING activating delivery systems and indirect STING activating therapies). In addition, it describes key variants of STING and the non-immunological functions of the pathway (cell apoptosis, autophagy, cell proliferation and others).

Chapter 4 includes detailed assessment on more than 50 therapeutics targeting STING pathway; the analysis  is based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discover, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.

Chapter 5 highlights various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography)..

Chapter 6 features elaborate profiles of key players that are engaged in the development of agonist therapeutics targeting STING Pathways (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.

Chapter 7 provides information on the various grants that were awarded to research institutes conducting projects related to therapeutics targeting STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section. It also includes an analysis of on grant attractiveness.

Chapter 8 features the detailed analysis of all the big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration. In addition, the chapter features a benchmarking analysis of the aforementioned players.

Chapter 9 presents an analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.

Chapter 10 presents a detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players (in terms of number of publications), region , first author organization and key journals (in terms of number of articles published in this domain). 

Chapter 11 features an elaborate analysis and discussion of partnerships / collaborations that have been established in this domain, over the period 2015 - Q1 2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions,  R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals. The chapter highlights analysis based on year of partnerships, type of partnership model, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of partnerships inked), and region.

Chapter 12 provides analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies engaged in this field. The chapter highlights analysis based on the number of funding instances, amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical region.

Chapter 13 features a comprehensive market forecast, highlighting the future potential of novel technologies designed for the development of STING pathway modulators till 2030, based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] type of STING modulator (agonist and antagonist), [B] type of molecule (non-nucleotides, cyclic dinucleotides, live biotherapeutics, oncolytic viruses, synthetic peptides and others) [C] therapeutic area (oncological disorders, inflammatory disorders, infectious diseases and other disorders), [D] route of administration (intratumoral, intravenous, oral, subcutaneous and others), [E] type of technology licensing payment / revenue (upfront payments and milestone payments) and [F] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of market for therapeutics targeting STING pathway and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 14 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.

Chapter 15 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Stimulator of Interferon Genes (STING) Pathway 
3.2. STING Signaling 
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial Host Defense

3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug Delivery Systems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of the STING Pathway
3.6. Concluding Remarks

4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. STING Pathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysis by Type of STING Modulator
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Line of Treatment

4.3. STING Pathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
4.3.4. Most Active Players

4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysis by Trial Recruitment Status
4.4.2. Analysis by Study Design
4.4.3. Analysis by Key Clinical Endpoints

5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway Targeting Technologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography

6. COMPANY PROFILES
6.1. Chapter Overview
6.2 STING Agonist Developers
6.2.1. Aduro Biotech
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: ADU-S100 (MIW815)
6.2.1.4. Recent Developments and Future Outlook

6.2.2. Bristol-Myers Squibb
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: BMS-986301
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Eisai
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: E7766
6.2.3.4. Recent Developments and Future Outlook

6.2.4 GlaxoSmithKline
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: GSK3745417
6.2.4.4. Recent Developments and Future Outlook

6.2.5. ImmuneSensor Therapeutics
6.2.5.1. Company Overview
6.2.5.2. Product Description: IMSA101

6.2.6. Merck
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MK-1454 and MK-2118
6.2.6.4. Recent Developments and Future Outlook

6.2.7. Noxopharm
6.2.7.1. Company Overview
6.2.7.2. Product Description: NOX66
6.2.7.3. Recent Developments and Future Outlook

6.2.8. Spring Bank Pharmaceuticals
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: SB 11285
6.2.8.4. Recent Developments and Future Outlook

6.2.9. Synlogic
6.2.9.1. Company Overview
6.2.9.2. Financial Information
6.2.9.3. Product Description: SYNB1891
6.2.9.4. Recent Developments and Future Outlook

6.3. STING Antagonist Developers
6.3.1 Avammune Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor Therapeutics
6.3.4. Nimbus Therapeutics
6.3.5. Sirenas
6.3.6. Spring Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe Therapeutics

7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting Therapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of Recipient Organization
7.3.10 Regional Distribution of Grant Recipients
7.3.11 Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis by Number of Grants
7.3.13 Analysis by Support Year and Amount Awarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis

8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big Pharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration

8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-Myers Squibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Takeda Pharmaceuticals

9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Roots Analysis Perspective

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. STING Pathway Targeting Therapeutics: Recent Publications
10.3.1. Analysis by Type of Publication
10.3.2. Analysis by Type of Publication and Year
10.3.3. Analysis by Study Objective
10.3.4. Analysis by Popular Keywords 
10.3.5. Analysis by Type of STING Modulator
10.3.6. Analysis by Target Pathway
10.3.7. Analysis by Therapeutic Area
10.3.8. Analysis by Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number of Publications
10.3.11. Leading Players: Geographical Analysis by Number of Publications
10.3.12. Analysis by First Author Organization
10.3.13. Key Journals: Analysis by Number of Publications

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics: Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Number of Partnerships

11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Number of partnerships
11.3.7.2. Intercontinental and Intracontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of STING Modulator
12.3.6. Analysis by Therapeutic Area
12.3.6 Analysis by Amount Invested and Type of STING Technology Platform
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Investors: Analysis by Number of Funding Instances
12.3.9. Geographical Analysis by Amount Invested
12.4. Concluding Remarks

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global STING Pathway Targeting Technologies Market, 2020-2030
13.3.1. STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting Technologies Market: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting Technologies Market for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting Technologies Market for Antagonist, 2020-2030

13.3.4. STING Pathway Targeting Technologies Market: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030

13.3.5. STING Pathway Targeting Technologies Market: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting Technologies Market for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting Technologies Market for Other Routes, 2020-2030

13.3.6. STING Pathway Targeting Technologies Market: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting Technologies Market for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting Technologies Market for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030

13.3.7. STING Pathway Targeting Technologies Market: Distribution by Geography
13.3.7.1. STING Pathway Targeting Technologies Market in North America, 2020-2030
13.3.7.2. STING Pathway Targeting Technologies Market in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030

14. EXECUTIVE INSIGHTS

15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 STING Signaling Pathway
Figure 4.1 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator
Figure 4.2 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule
Figure 4.3 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator and Type of Molecule
Figure 4.4 STING Pathway Targeting Therapeutics: Distribution by Phase of Development
Figure 4.5 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule and Phase of Development
Figure 4.6 STING Pathway Targeting Therapeutics: Distribution by Therapeutic Area
Figure 4.7 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator and Target Indication(s)
Figure 4.8 STING Pathway Targeting Therapeutics: Distribution by Type of Therapy
Figure 4.9 STING Pathway Targeting Therapeutics: Distribution by Route of Administration
Figure 4.10 STING Pathway Targeting Therapeutics: Distribution by Line of Treatment
Figure 4.111 STING Pathway Targeting Therapeutics Developers: Distribution by Year of Establishment
Figure 4.12 STING Pathway Targeting Therapeutics Developers: Distribution by Company Size
Figure 4.13 STING Pathway Targeting Therapeutics Developers: Distribution by Leading Player
Figure 4.14 STING Pathway Targeting Therapeutics Developers: Distribution by Type of STING Modulator
Figure 4.15 STING Pathway Targeting Therapeutics Developers: Distribution by Type of Molecule
Figure 4.16 STING Pathway Targeting Therapeutics Developers: Analysis by Geography
Figure 4.17 Clinical Trials: Distribution by Trial Recruitment Status
Figure 4.18 Clinical Trials: Grid Analysis
Figure 4.19 Clinical Trials: Distribution by Study Design
Figure 4.20 Clinical Trials: Benchmarking of Industry Players by Number of Trials across Key Therapeutics Indications
Figure 4.21 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Figure 5.1 STING Pathway Targeting Technologies: Distribution by Type of Modulator
Figure 5.2 STING Pathway Targeting Technologies: Distribution by Type of Molecule
Figure 5.3 STING Pathway Targeting Technologies: Distribution by Year of Establishment
Figure 5.4 STING Pathway Targeting Technologies: Distribution by Company Size
Figure 5.5 STING Pathway Targeting Technologies: Distribution by Geography
Figure 6.1 Aduro Biotech: Net Revenues, FY 2015- Q1 2020 (USD Million)
Figure 6.2 Bristol-Myers Squibb: Net Revenues, FY 2015- Q1 2020 (USD Million)
Figure 6.3 Eisai: Net Revenues, FY 2015 - Q1 2020 (USD Billion)
Figure 6.4 GlaxoSmithKline: Net Revenues, FY 2015 - Q1 2020 (USD Billion)
Figure 6.5 Merck: Net Revenues, FY 2015 - Q1 2020 (USD Billion)
Figure 6.6 Spring Bank Pharmaceuticals: Net Working Capital, FY 2015 – FY 2019 (USD Million)
Figure 6.7 Synlogic: Net Revenues, FY 2016 - Q1 2020 (USD Million)
Figure 7.1 Academic Grant Analysis: Year–wise Trend
Figure 7.2 Academic Grant Analysis: Distribution by Amount Awarded (USD Million)
Figure 7.3 Academic Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Academic Grant Analysis: Distribution by Support Period
Figure 7.5 Academic Grant Analysis: Distribution by Funding Mechanism
Figure 7.6 Academic Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Academic Grant Analysis: Distribution by Activity of Grant
Figure 7.8 Academic Grant Analysis: Most Popular NIH Departments
Figure 7.9 Academic Grant Analysis: Distribution by Recipient Organization
Figure 7.10 Academic Grant Analysis: Regional Distribution by Recipient Organization
Figure 7.11 Academic Grant Analysis: Distribution by Number of Grants and Amount Awarded
Figure 7.12 Prominent Project Leaders: Distribution by Number of Grants Awarded
Figure 7.13 Prominent Project Leaders: Distribution by Amount Awarded
Figure 7.14 Academic Grant Analysis: Distribution by Support Period
Figure 7.15 Academic Grant Analysis: Distribution by Study Section
Figure 7.16 Academic Grant Analysis: Grant Attractiveness
Figure 8.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Players: Heat Map Analysis of Other Pharmaceutical Companies
Figure 8.3 Big Pharma Players: Analysis by Portfolio Diversity
Figure 8.4 Big Pharma Players: Analysis by Type of Molecule
Figure 8.5 Big Pharma Players: Analysis by Phase of Development
Figure 8.6 Big Pharma Players: Analysis by Diversity of Therapeutic Areas
Figure 8.7 Big Pharma Players: Analysis by Type of Therapy
Figure 8.8 Big Pharma Players: Analysis by Route of Administration
Figure 8.9 Spider Web Analysis: AbbVie
Figure 8.10 Spider Web Analysis: Bayer
Figure 8.11 Spider Web Analysis: Bristol-Myers Squibb
Figure 8.12 Spider Web Analysis: Celgene
Figure 8.13 Spider Web Analysis: Eisai
Figure 8.14 Spider Web Analysis: Eli Lily
Figure 8.15 Spider Web Analysis: Genentech
Figure 8.16 Spider Web Analysis: GlaxoSmithKline
Figure 8.17 Spider Web Analysis: Merck
Figure 8.18 Spider Web Analysis: Novartis
Figure 8.19 Spider Web Analysis: Novo Nordisk
Figure 8.20 Spider Web Analysis: Pfizer
Figure 8.21 Spider Web Analysis: Roche
Figure 8.22 Spider Web Analysis: Takeda Pharmaceuticals
Figure 9.1. Benchmark Analysis of Start-ups: Distribution by Portfolio Diversity
Figure 9.2 Benchmark Analysis of Start-ups: Distribution by Type of Molecule
Figure 9.3 Benchmark Analysis of Start-ups: Distribution by Phase of Development
Figure 9.4 Benchmark Analysis of Start-ups: Distribution by Therapeutic Area
Figure 9.5 Benchmark Analysis of Start-ups: Distribution by Location
Figure 9.6 Benchmark Analysis of Start-ups: Distribution by Funding Amount
Figure 9.7 Benchmark Analysis of Start-ups: Distribution by Number of Investors
Figure 9.8 Benchmark Analysis of Start-ups: Distribution by Progression in Funding
Figure 9.9 Benchmark Analysis of Start-ups: Distribution by Partnership Activity
Figure 9.10 Benchmark Analysis of Start-ups: Distribution by Patent Portfolio
Figure 9.11 Benchmark Analysis of Start-ups: Distribution by Grant Portfolio
Figure 9.12 Benchmark Analysis of Start-ups: Distribution by Number of Publications
Figure 9.13 Start-up Health Indexing: Roots Analysis Perspective
Figure 10.1 Publication Analysis: Cumulative Year-wise Trend, 2015 - Q1 2020
Figure 10.2 Recent Publications: Distribution by Type of Publication
Figure 10.3 Recent Publications: Distribution by Year and Type of Publication
Figure 10.4 Recent Publications: Distribution by Study Objective
Figure 10.5 Recent Publications: Distribution by Emerging Focus Area
Figure 10.6 Recent Publications: Distribution by Type of Molecule
Figure 10.7 Recent Publications: Distribution by Target Pathway
Figure 10.8 Recent Publications: Distribution by Therapeutic Area
Figure 10.9 Recent Publications: Distribution by Type of Molecule and Therapeutic Area
Figure 10.10 Recent Publications: Distribution by Type of Publisher
Figure 10.11 Most Active Players: Distribution by Number of Publications
Figure 10.12 Leading Players: Geographical Distribution by Number of Publications
Figure 10.13 Leading Players: Distribution by First Author Organization
Figure 10.14 Key Journals: Distribution by Number of Publications
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015 - Q1 2020
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of STING Modulator
Figure 11.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.6 Partnerships and Collaborations: Year-wise Trend by Type of Therapeutic Area
Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Figure 11.8 Partnership and Collaborations: Distribution by Technology Platform
Figure 11.9 Most Active Players: Distribution by Number of Partnerships
Figure 11.10 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 11.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distributions
Figure 12.1 Funding and Investments: Distribution by Year of Establishment and Type of Funding, 2015 - Q1 2020
Figure 12.2 Funding and Investments: Distribution by Type of STING Modulator and Type of Funding
Figure 12.3 Funding and Investments: Cumulative Year-wise Trend, 2015 - Q1 2020
Figure 12.4 Funding and Investments: Cumulative Amount Invested by Year, 2015 - Q1 2020 (USD Million)
Figure 12.5 Funding and Investments: Distribution by Type of Funding
Figure 12.6 Funding and Investments: Year-wise Trend of Amount Invested, 2015 - Q1 2020 (USD Million)
Figure 12.7 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 12.8 Funding and Investments: Summary of Investments, 2015 - Q1 2020 (USD Million)
Figure 12.9 Funding and Investments: Distribution by Type of Modulator
Figure 12.10 Funding and Investments: Distribution by Therapeutic Area
Figure 12.12 Funding and Investments: Distribution of Amount Invested by Therapeutic Area, 2015 - Q1 2020
Figure 12.13 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 12.14 Most Active Players: Distribution by Number of Instances
Figure 12.15 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 12.16 Most Active Investors: Distribution by Amount Invested (USD Million)
Figure 12.17 Funding and Investment: Geographical Distribution by Amount Invested (USD Million)
Figure 12.18 Funding and Investment: Summary
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 STING Pathway Targeting Therapeutics: Payment Structure
Figure 13.3 Global STING Pathway Targeting Technologies Market, 2020-2030 (USD Million)
Figure 13.4 STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030 (USD Million)
Figure 13.5 STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030 (USD Million)
Figure 13.6 STING Pathway Targeting Technologies Market for Agonists, 2020-2030 (USD Million)
Figure 13.7 STING Pathway Targeting Technologies Market for Antagonists, 2020-2030 (USD Million)
Figure 13.8 STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 13.9 STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030 (USD Million)
Figure 13.10 STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030 (USD Million)
Figure 13.11 STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 13.12 STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030 (USD Million)
Figure 13.13 STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030 (USD Million)
Figure 13.14 STING Pathway Targeting Technologies Market for Oral Route, 2020-2030 (USD Million)
Figure 13.15 STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030 (USD Million)
Figure 13.16 STING Pathway Targeting Technologies Market for Other Routes, 2020-2030 (USD Million)
Figure 13.17 STING Pathway Targeting Technologies Market for Non-nucleotides, 2020-2030 (USD Million)
Figure 13.18 STING Pathway Targeting Technologies Market for Cyclic Dinucleotides, 2020-2030 (USD Million)
Figure 13.19 STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030 (USD Million)
Figure 13.20 STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030 (USD Million)
Figure 13.21 STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030 (USD Million)
Figure 13.22 STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030 (USD Million)
Figure 13.23 STING Pathway Targeting Technologies Market in North America, 2020-2030 (USD Million)
Figure 13.24 STING Pathway Targeting Technologies Market in Europe, 2020-2030 (USD Million)
Figure 13.25 STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Role of DNA and RNA viruses in STING Signaling
Table 4.1 STING Pathway Targeting Therapeutics: Development Pipeline
Table 4.2 STING Pathway Targeting Therapeutics: Information on Phase of Development and Target Indication
Table 4.3 STING Pathway Targeting Therapeutics: Information on Type of Therapy and Route of Administration
Table 4.4 STING Pathway Targeting Therapeutics: Developer Landscape
Table 4.5 STING Pathway Targeting Therapeutics: List of Clinical Trials
Table 5.1 STING Pathway Targeting Technologies: List of Technology Developers
Table 6.1 Aduro Biotech: Key Highlights
Table 6.2 Aduro Biotech: Key Characteristics of ADU-S100 (MIW815)
Table 6.3 Aduro Biotech: Recent Developments and Future Outlook
Table 6.4 Bristol-Myers Squibb: Key Highlights
Table 6.5 Bristol-Myers Squibb: Key Characteristics of BMS-986301
Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.7 Eisai: Key Highlights
Table 6.8 Eisai: Key Characteristics of E7766
Table 6.9 Eisai: Recent Developments and Future Outlook
Table 6.10 GlaxoSmithKline: Key Highlights
Table 6.11 GlaxoSmithKline: Key Characteristics of GSK3745417
Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.13 ImmuneSensor Therapeutics: Key Highlights
Table 6.14 ImmuneSensor Therapeutics: Key Characteristics of IMSA101
Table 6.15 Merck: Key Highlights
Table 6.16 Merck: Key Characteristics of MK-1454 and MK-2118
Table 6.17 Merck: Recent Developments and Future Outlook
Table 6.18 Noxopharm: Key Highlights
Table 6.19 Noxopharm: Key Characteristics of NOX66
Table 6.20 Noxopharm: Recent Developments and Future Outlook
Table 6.21 Spring Bank Pharmaceuticals: Key Highlights
Table 6.22 Spring Bank Pharmaceuticals: Key Characteristics of SB 11285
Table 6.23 Spring Bank Pharmaceuticals: Recent Developments and Future Outlook
Table 6.24 Synlogic: Key Highlights
Table 6.25 Synlogic: Key Characteristics of SYNB1891
Table 6.26 Synlogic: Recent Developments and Future Outlook
Table 6.27 Avammune Therapeutics: Key Highlights
Table 6.28 Curadev Key Highlights
Table 6.29 Nimbus Therapeutics: Key Highlights
Table 6.30 Sirenas: Key Highlights
Table 6.31 STINGINN: Key Highlights
Table 7.1 STING Pathway Targeting Therapeutics: List of Academic Grants, 2015 - Q1 2020
Table 7.2 Grant Analysis: List of Most Attractive Grants
Table 10.1 STING Pathway Targeting Therapeutics: List of Recent Publications, 2019–Q1 2020
Table 11.1 STING Pathway Targeting Therapeutics: List of Partnerships, 2015-Q1 2020
Table 11.2 Most Active Players: Distribution by Number of Partnerships
Table 12.1 STING Pathway Targeting Therapeutics: List of Funding Instances, 2015- Q1 2020
Table 12.2 Funding and Investments: Summary
Table 13.1 Technology Licensing Deals: Milestone Payments
Table 13.2 STING Pathway Targeting TherapeuticsMarket: Average Upfront and Milestone Payments, 2015 - Q1 2020 (USD Million)
Table 16.1 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator
Table 16.2 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule
Table 16.3 STING Pathway Targeting Therapeuticst: Distribution by Type of Modulator and Type of Molecule
Table 16.4 STING Pathway Targeting Therapeutics: Distribution by Phase of Development
Table 16.5 STING Pathway Targeting Therapeutics: Distribution by Phase of Development and Type of Molecule
Table 16.6 STING Pathway Targeting Therapeutic: Distribution by Therapeutic Area
Table 16.7 STING Pathway Targeting Therapeutics: Distribution by Type of Modulator and Leading Indication
Table 16.8 STING Pathway Targeting Therapeutics: Distribution by Type of Therapy
Table 16.9 STING Pathway Targeting Therapeutics: Distribution by Route of Administration
Table 16.10 STING Pathway Targeting Therapeutics: Distribution by Line of Treatment
Table 16.11 STING Pathway Targeting Therapeutics: Distribution of Industry Players by Year of Establishment
Table 16.12 STING Pathway Targeting Therapeutics: Distribution by Company Size
Table 16.13 STING Pathway Targeting Therapeutics: Distribution by Leading Player
Table 16.14 STING Pathway Targeting Therapeutics: Distribution by Type of STING Modulator
Table 16.15 STING Pathway Targeting Therapeutics: Distribution by Type of Molecule
Table 16.16 STING Pathway Targeting Therapeutics: Analysis by Geography
Table 16.17 Clinical Trials: Distribution by Trial Recruitment Status
Table 16.18 Clinical Trials: Grid Analysis
Table 16.19 Clinical Trials: Distribution by Study Design
Table 16.20 Clinical Trials: Benchmarking of Industry Players by Number of Trials across Key Therapeutics Indications
Table 16.21 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Table 16.22 STING Pathway Targeting Technologies: Distribution by Type of Modulator
Table 16.23 STING Pathway Targeting Technologies: Distribution by Type of Molecule
Table 16.24 STING Pathway Targeting Technologies: Distribution by Year of Establishment
Table 16.25 STING Pathway Targeting Technologies: Distribution by Company Size
Table 16.26 STING Pathway Targeting Technologies: Distribution by Geography
Table 16.27 Aduro Biotech: Net Revenues, FY 2015- Q1 2020 (USD Million)
Table 16.28 Bristol-Myers Squibb: Net Revenues, FY 2015- Q1 2020 (USD Million)
Table 16.29 Eisai: Net Revenues, FY 2015- Q1 2020 (USD Billion)
Table 16.30 GlaxoSmithKline: Net Revenues, FY 2015- Q1 2020 (USD Billion)
Table 16.31 Merck: Net Revenues, FY 2015- Q1 2020 (USD Billion)
Table 16.32 Noxopharm: Net Income FY 2016-Q1 2020 (USD Million)
Table 16.33 Spring Bank Pharmaceuticals: Net Working Capital, FY 2015 – 2019 (USD Million)
Table 16.34 Synlogic: Net Revenues, FY 2016- Q1 2020 (USD Million)
Table 16.35 Academic Grant Analysis: Year –wise Trend of Award
Table 16.36 Academic Grant Analysis: Distribution by Amount Awarded (USD Million)
Table 16.37 Academic Grant Analysis: Distribution by Administering Institute Center
Table 16.38 Academic Grant Analysis: Distribution by Support Period
Table 16.39 Academic Grant Analysis: Distribution by Funding Mechanism
Table 16.40 Academic Grant Analysis: Distribution by Type of Grant Application
Table 16.41 Academic Grant Analysis: Distribution by Activity of Grant
Table 16.42 Academic Grant Analysis: Most Popular NIH Department
Table 16.43 Academic Grant Analysis: Distribution by Recipient Organization
Table 16.44 Academic Grant Analysis: Regional Distribution by Recipient Organization
Table 16.45 Academic Grant Analysis: Distribution by Number of Grants and Amount Invested
Table 16.46 Prominent Project Leaders: Distribution by Number of Grants Awarded
Table 16.47 Prominent Project Leaders: Distribution by Number of Amount Invested
Table 16.48 Academic Grant Analysis: Distribution by Support Period
Table 16.49 Academic Grant Analysis: Distribution by Study Section
Table 16.50 Grant Attractiveness: Relative Attractiveness
Table 16.51 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Table 16.52 Big Pharma Players: Heat Map Analysis of Other Pharmaceutical Companies
Table 16.53 Big Pharma Players: Analysis by Portfolio Diversity
Table 16.54 Big Pharma Players: Analysis by Phase of Development
Table 16.55 Big Pharma Players: Analysis by Type of Molecule
Table 16.56 Big Pharma Players: Analysis by Diversity of Therapeutic Areas
Table 16.57 Big Pharma Players: Analysis by Type of Therapy
Table 16.58 Big Pharma Players: Analysis by Route of Administration
Table 16.59 Spider Web Analysis: AbbVie
Table 16.60 Spider Web Analysis: Bayer
Table 16.61 Spider Web Analysis: Bristol-Myers Squibb
Table 16.62 Spider Web Analysis: Celgene
Table 16.63 Spider Web Analysis: Eisai
Table 16.64 Spider Web Analysis: Eli Lily
Table 16.65 Spider Web Analysis: Genentech
Table 16.66 Spider Web Analysis: GlaxoSmithKline
Table 16.67 Spider Web Analysis: Merck
Table 16.68 Spider Web Analysis: Novartis
Table 16.69 Spider Web Analysis: Novo Nordisk
Table 16.70 Spider Web Analysis: Pfizer
Table 16.71 Spider Web Analysis: Roche
Table 16.72 Spider Web Analysis: Takeda Pharmaceuticals
Table 16.73 Benchmark Analysis of Start-ups: Distribution by Portfolio Diversity
Table 16.74 Benchmark Analysis of Start-ups: Distribution by Phase of Development
Table 16.75 Benchmark Analysis of Start-ups: Distribution by Therapeutic Areas
Table 16.76 Benchmark Analysis of Start-ups: Distribution by Type of Molecule
Table 16.77 Benchmark Analysis of Start-ups: Distribution by Location
Table 16.78 Benchmark Analysis of Start-ups: Distribution by Funding Amount
Table 16.79 Benchmark Analysis of Start-ups: Distribution by Number of Investors
Table 16.80 Benchmark Analysis of Start-ups: Distribution by Progression in Funding
Table 16.81 Benchmark Analysis of Start-ups: Distribution by Partnership Activity
Table 16.82 Benchmark Analysis of Start-ups: Distribution by Patent Portfolio
Table 16.83 Benchmark Analysis of Start-ups: Distribution by Grant Portfolio
Table 16.84 Benchmark Analysis of Start-ups: Distribution by Number of Publications
Table 16.85 Start-up Health Indexing: Roots Analysis Perspective
Table 16.86 Publication Analysis: Cumulative Year-wise Trend, 2015- Q1 2020
Table 16.87 Publication Analysis: Distribution by Type of Publication
Table 16.88 Publication Analysis: Distribution by Type of Publication and Year
Table 16.89 Publication Analysis: Distribution by Study Objective
Table 16.90 Publication Analysis: Distribution by Emerging focus Area
Table 16.91 Publication Analysis: Distribution by Type of STING Modulator
Table 16.92 Publication Analysis: Distribution by Target Pathway
Table 16.93 Publication Analysis: Distribution by Therapeutic Area
Table 16.94 Publication Analysis: Distribution by Therapeutic Area and Type of STING Modulator
Table 16.95 Publication Analysis: Distribution by Type of Publisher
Table 16.96 Most Active Players: Distribution by Number of Publications
Table 16.97 Leading Players: Geographical Distribution by Number of Publications
Table 16.98 Publication Analysis: Distribution by First Author Organization
Table 16.99 Key Journals: Distribution by Number of Publications
Table 16.100 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-Q1 2020
Table 16.101 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.102 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 16.103 Partnerships and Collaborations: Distribution by Type of STING Modulator
Table 16.104 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.105 Partnerships and Collaborations: Year-wise Trend by Type of Therapeutic Area
Table 16.106 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Table 16.107 Partnership and Collaborations: Distribution by Technology Platform
Table 16.108 Most Active Players: Distribution by Number of Partnerships
Table 16.109 Most Active Player: Geographical Distribution by Number of Partnerships
Table 16.110 Partnerships and Collaborations: Intercontinental and Intracontinental Distributions
Table 16.111 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2015-Q1 2020
Table 16.112 Funding and Investments: Distribution by Type of STING Modulator and Type of Funding
Table 16.113 Funding and Investments: Cumulative Year-wise Trend, 2015- Q1 2020
Table 16.114 Funding and Investments: Cumulative Amount Invested by Year, 2015- Q1 2020 (USD Million)
Table 16.115 Funding and Investments: Distribution by Type of Funding
Table 16.116 Funding and Investments: Year-wise Trend of Amount Invested, 2015-Q1 2020 (USD Million)
Table 16.117 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 16.118 Funding and Investments: Summary of Investments, 2015-Q1 2020 (USD Million)
Table 16.119 Funding and Investments: Analysis by Type of Modulator
Table 16.120 Funding and Investments: Distribution by Therapeutic Area
Table 16.121 Funding and Investments: Distribution of Amount Invested in Therapeutic Areas, 2015-Q1 2020
Table 16.122 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Table 16.123 Most Active Players: Distribution by Number of Instances
Table 16.124 Most Active Players: Distribution by Amount Raised (USD Million)
Table 16.125 Most Active Investors: Distribution by Amount Raised (USD Million)
Table 16.126 Funding and Investment: Geographical Distribution by Amount Invested (USD Million)
Table 16.127 Funding Instances: Funding and Investment Summary
Table 16.128 Global STING Pathway Targeting Technologies Market: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.129 STING Pathway Targeting Technologies Market for Upfront Payments: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.130 STING Pathway Targeting Technologies Market for Milestone Payments: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.131 STING Pathway Targeting Technologies Market for Agonist: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.132 STING Pathway Targeting Technologies Market for Antagonist: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.133 STING Pathway Targeting Technologies Market for Oncological Disorders: Base, Conservative and Optimistic Scenario, 2020-203 (USD Million)
Table 16.134 STING Pathway Targeting Technologies Market for Inflammatory Disorders: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.135 STING Pathway Targeting Technologies Market for Infectious Diseases: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.136 STING Pathway Targeting Technologies Market for Other Therapeutic Areas: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.137 STING Pathway Targeting Technologies Market for Intratumoral Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.138 STING Pathway Targeting Technologies Market for Intravenous Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.139 STING Pathway Targeting Technologies Market for Oral Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.140 STING Pathway Targeting Technologies Market for Subcutaneous Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.141 STING Pathway Targeting Technologies Market for Other Route: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.142 STING Pathway Targeting Technologies Market for Non-nucleotides: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.143 STING Pathway Targeting Technologies Market for Cyclic Dinucleotides: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.144 STING Pathway Targeting Technologies Market for Live Biotherapeutics: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.145 STING Pathway Targeting Technologies Market for Oncolytic Viruses: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.146 STING Pathway Targeting Technologies Market for Synthetic Peptides: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.147 STING Pathway Targeting Technologies Market for Other Molecules: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.148 STING Pathway Targeting Technologies Market in North America: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.149 STING Pathway Targeting Technologies Market in Europe: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 16.150 STING Pathway Targeting Technologies Market in Asia-Pacific: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)

List Of Companies

1. 6 Dimensions Capital
2. Aalborg University
3. Aarhus University
4. AbbVie
5. Abingworth
6. Academia Sinica
7. Actym Therapeutics
8. Aduro Biotech
9. Aescap 2.0
10. AJU IB Investment
11. Alaska Permanent Fund
12. Alexandria Venture Investments
13. All India Institute of Medical Sciences
14. Allergan
15. Ally Bridge Group
16. Almac Diagnostics
17. Alpine BioVentures
18. Atlas Venture
19. Amgen
20. Anhui University of Science and Technology
21. Arbutus Biopharma
22. ARCH Venture Partners
23. Arctic Aurora LifeScience
24. Arix Bioscience
25. Arizona State University
26. Army Medical University
27. Arrowpoint Partners
28. Artimmune
29. Astellas Pharma
30. AstraZeneca
31. Avammune Therapeutics
32. Baruch S. Blumberg Institute
33. Bayer
34. Baylor University Medical Center
35. Beatson Institute
36. BellBrook Labs
37. Beth Israel Deaconess Medical Center
38. Bicycle Therapeutics
39. Bill & Melinda Gates Foundation
40. Biogen
41. BioInnovation Institute
42. Institut de Recerca Biomèdica de Lleida (IRBLleida)
43. BioNovion
44. Boehringer Ingelheim
45. Boston Children's Hospital
46. Boston University
47. Boxer Capital
48. Bpifrance
49. Brigham And Women's Hospital
50. Bristol-Myers Squibb
51. BWG Invest
52. California Institute for Biomedical Research
53. Cambridge Innovation Capital
54. The Beatson Institute
55. Cancer Therapeutics CRC
56. Canterbury Urology Research Trust
57. Casdin Capital
58. Case Western Reserve University
59. Celgene
60. Central South University
61. Center for AIDS Research
62. CHA University
63. Chaim Sheba Medical Center
64. Charité Universitätsmedizin Berlin
65. Charles River Laboratories
66. Charles University
67. Chengwei Capital
68. China Pharmaceutical University
69. Chinese Academy of Agricultural Sciences
70. Chinese Academy of Medical Sciences
71. Chongqing Medical University
72. Chulalongkorn University
73. Cincinnati Childern's Hospital Medical Center
74. CLI Ventures
75. Clough Capital Partners
76. Codiak BioSciences
77. College of Biotechnology Southwest University
78. Columbia University Medical Center
79. CordenPharma
80. Cristal Therapeutics
81. CSL
82. CST Investment Funds
83. Curadev Pharma
84. Curative Ventures
85. Czech Academy of Sciences
86. Daiichi Sankyo
87. Dalhousie University
88. Dana-Farber Cancer Institute
89. David Geffen School of Medicine
90. Deaconess Medical Center
91. Deerfield Management
92. Dermatology Hospital of Fuzhou
93. Dezful University of Medical Sciences
94. DiscoveryBioMed
95. Duke University Medical Center
96. Ecole polytechnique fédérale de Lausanne
97. EcoR1 Capital
98. Ege University
99. Eight Roads Ventures
100. Eisai
101. Eli Lilly
102. Emory University School of Medicine
103. Eulji University School of Medicine
104. European Institute of Oncology
105. Evonik Nutrition & Care
106. Feinstein Institutes for Medical Research
107. Ferring Pharmaceuticals
108. Fidelity Biosciences
109. Flagship Pioneering
110. Florida State University
111. Fluorinov Pharma
112. Fondazione IRCCS Istituto Nazionale dei Tumori
113. Foresite Capital 
114. Fox Chase Cancer Center
115. F-Prime Capital
116. Franklin Advisers
117. Frazier Healthcare Partners
118. Fredrick National Laboratory for Cancer Research
119. Fudan University
120. Fujian Medical University
121. Fund+
122. Gachon University
123. Geisel School of Medicine
124. Genentech
125. GenesisCare
126. George Clinical
127. Georges-Francois Leclerc Cancer Center- UNICNACER
128. Ghent University Hospital
129. Gifu University Graduate School of Medicine
130. Gilead Sciences
131. Ginkgo Bioworks
132. GlaxoSmithKline
133. Green Park & Golf Ventures
134. Griffith University
135. Guangzhou Medical University
136. Guilin Medical University
137. Gunma University
138. H3Biomedicine
139. Hacettepe University
140. Hackensack University John Theurer Cancer Center
141. Hallym University
142. Harbin Veterinary Research Institute
143. Harvard Medical School
144. HBM Partners
145. Health Wildcatters
146. Helmholtz Centre for Infection Research
147. Henan Agricultural University
148. HitGen
149. Hong Kong University of Science & Technology
150. Huntsman Cancer Institute
151. Icahn School of Medicine at Mount Sinai
152. IFM Therapeutics
153. ImaBiotech
154. ImmuneSensor Therapeutics
155. IMMvention Therapeutix
156. Inflammatory Bowel Disease Center
157. Inserm
158. Institute of Materia Medica
159. Institute of Radiation Biology
160. Institut Curie
161. Gustave Roussy
162. Institute for Personalized Medicine
163. Institute of Macromolecular Chemistry ASCR
164. Institute of Pathogen Biology 
165. InvivoGen
166. Invus
167. Iowa State University
168. iOx Therapeutics
169. IQVIA
170. Istanbul Technical University
171. Istituto Superiore di Sanità
172. iTeos Therapeutics
173. James Graham Brown Cancer Center
174. Janus Capital Management
175. Japanese Foundation for Cancer Research
176. Jazz Pharmaceuticals 
177. Jennison Associates
178. Jilin University
179. Johns Hopkins University School of Medicine
180. Juntendo University School of Medicine
181. Kalinga Institute of Industrial Technology
182. Kangwon National University
183. Karmanos Cancer Institute
184. Karol Marcinkowski University of Medical Sciences
185. Karolinska Institute
186. Kazia Therapeutics
187. Keystone Symposia
188. Kindeva Drug Delivery
189. Kobe University
190. Korea Advanced Institute of Science and Technology
191. KU Leuven
192. Kuang Tien General Hospital Cancer Center
193. Kunming University of Science and Technology
194. RIKEN Center for Integrative Medical Sciences Laboratory for Cell Signaling 
195. Lerner Research Institute
196. Les Laboratoires Servier
197. LIDDS
198. Life Science Venture Capital Management
199. Lightstone Ventures
200. Linköping University
201. Longwood Fund
202. Lund University
203. Magee- Womens Research Institute
204. Maria Skłodowska-Curie National Research Institute of Oncology
205. Mary Crowley Cancer Research
206. Massachusetts General Hospital
207. Massachusetts Green High Performance Computing Center
208. Massachusetts Institute of Technology
209. Max Planck Institute for Immunobiology and Epigenetics
210. Mayo Clinic
211. Medical College of Wisconsin
212. Medigen
213. Medison Finance
214. Meharry Medical College
215. Memorial Sloan Kettering Cancer Center
216. Merck
217. Mersana Therapeutics
218. Michigan State University
219. Mirna Therapeutics
220. Moffitt Cancer Center
221. Monash University
222. Morningside Group
223. Mount Sinai Hospital
224. MPM Capital
225. MUSC Hollings Cancer Center
226. Nanchang University
227. Nanjing Agricultural University
228. Nanjing Medical University
229. Nankai Univeristy
230. Nanobiotix 
231. National Center of Biomedical Analysis
232. National Institutes of Biomedical Innovation, Health and Nutrition
233. National Institutes of Health
234. National Tsing Hua University
235. National Yang-Ming University
236. New Enterprise Associates
237. New York Medical College
238. Newcastle University
239. NEXT Oncology
240. Nimbus Therapeutics
241. Ningxia university
242. Northwest A&F University
243. Northwestern University
244. Novartis
245. Novo Nordisk
246. Noxopharm
247. Nyenburgh Holding
248. Ohio State University College of Medicine
249. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
250. Oklahoma State University 
251. Omega Funds
252. OncoArendi Therapeutics
253. Oncology Impact Fund
254. OnCore Biopharma
255. OrbiMed HealthCare Fund Management
256. Oregon Health & Science University
257. Cormorant Asset Management
258. Osaka City University
259. Otsuka Holdings
260. Otto von Guericke University Magdeburg
261. Pasteur Institute
262. Peking University
263. Penn State College of Medicine
264. Perceptive Advisors
265. Pfizer
266. Portage Biotech
267. Precision for Medicine
268. Princeton University
269. Providence Cancer Institute 
270. Purdue University
271. Qatar Investment Authority
272. Quan Capital
273. Queen's University
274. RA Capital Management
275. Radboudumc
276. Rambam Health Care Center
277. Recepta Biopharma
278. Research Institute of Clinical Medicine
279. Roche
280. Rock Springs Capital Management
281. Rockefeller University
282. Roivant Sciences
283. Royal Marsden NHS Foundation Trust
284. Royal North Shore Hospital
285. RTW Investments
286. Rush University Medical Center
287. Ryvu Therapeutics
288. Salk Institute for Biological Studies
289. Sanford Burnham Prebys Medical Discovery Institute
290. Sanford Cancer Center 
291. Sanofi
292. Sapienza University
293. Schrödinger
294. Scientipôle
295. Seoul National Univesity
296. Sequoia Capital
297. Severance Hospital
298. SFPI
299. Shandong University
300. Shanghai Jiao Tong University
301. Shire
302. Sichuan Agricultural University
303. Sichuan University
304. Silicon Therapeutics
305. Sirenas
306. Sirona Capital
307. Smorodintsev Research Institute of Influenza
308. SMS-oncology
309. Société Régionale d'Investissement de Wallonie
310. SOTIO
311. South China Agricultural University
312. Southern Medical University
313. Spring Bank Pharmaceuticals
314. Springhood Ventures
315. SR One
316. St. Jude Children's Research Hospital
317. Saint Louis University School of Medicine
318. St. Vincent’s Hospital
319. Stanford University
320. Stimunity
321. STINGINN
322. Stingray Therapeutics
323. STipe Therapeutics
324. Stockholm University
325. Sun Yat-sen University Cancer Center
326. Sunstone Life Science Ventures
327. SV Life Sciences
328. Swiss Federal Institute of Technology
329. Sylvester Comprehensive Cancer Center
330. Synlogic
331. Takeda Pharmaceutical
332. Tbilisi State Medical University
333. Technical University of Munich
334. Technische Universität Dresden
335. Tempest Therapeutics
336. Texas A&M Health Science Center
337. The Lind Partners
338. Thomas Jefferson University
339. Tohoku University
340. Tongji University
341. Trillium Therapeutics
342. Trinity Biomedical Sciences Institute
343. Tsinghua University
344. ttopstart
345. Tufts University 
346. Tulane University 
347. TWINCORE-Centre for Experimental and Clinical Infection Research
348. Umeå University
349. UND Life Sciences
350. Universidad Autónoma de Madrid
351. Universidad Nacional de Río Cuarto
352. Universidade do Porto
353. Universidade Federal de Minas Gerais
354. Université de Lyon
355. Université libre de Bruxelles
356. University of Alabama Comprehensive Cancer Center
357. University of Arizona Cancer Center
358. University of Bonn
359. University of Buenos Aries
360. University of Calgary
361. University of California
362. University of Cambridge
363. University of Chicago
364. University of Cincinnati
365. University of Clermont Auvergne
366. University of Colorado School of Medicine
367. University of Connecticut School of Medicine
368. University of Delhi
369. University of Edinburgh
370. University of Ferrara
371. University of Florida
372. University of Freiburg
373. University of Glasgow
374. University of Groningen
375. University of Hong Kong
376. University of Illinois College of Medicine
377. University of Kansas
378. University of Konstanz
379. University of Maryland
380. University of Massachusetts Medical School
381. University of Miami
382. University of Michigan 
383. University of New South Wales
384. University of North Carolina
385. University of Orleans
386. University of Oxford
387. University of Pennsylvania
388. University of Piemonte Orientale
389. University of Pittsburgh
390. University of Queensland
391. University of Rhode Island
392. University of South China
393. University of South Florida
394. University of Southern California
395. University of Texas MD Anderson Cancer Center
396. University of Texas Southwestern Medical Center
397. University of Tokyo
398. University of Toronto
399. University of Utah 
400. University of Veterinary Medicine Hannover
401. University of Virginia
402. University of Washington
403. University of Zurich
404. University of Massachusetts Medical School
405. UPMC Hillman Cancer Center
406. Uppsala University
407. UT Southwestern Medical Center
408. Vanderbilt University
409. VENENUM Biodesign
410. Ventus Therapeutics
411. Versant Ventures
412. Vertex Ventures
413. VIVES Fund
414. Vyriad
415. Wake Forest School of Medicine
416. Washington University School of Medicine
417. Wayne State University
418. Weill Cornell Medicine
419. Weizmann Institute of Science
420. Wellington Management Company
421. Wikow Invest
422. Wuhan University
423. WuXi AppTec
424. Xi'an Jiaotong University
425. Xi'an Medical University
426. Xuzhou Medical University
427. Yale Cancer Center
428. Yangzhou University
429. Yokohama City University
430. York University
431. Zhejiang University School of Medicine
432. Zhengzhou University